

## Enhanced Susceptibility to Antifungal Oligopeptides in Yeast Strains Overexpressing ABC Multidrug Efflux Pumps<sup>∇</sup>

Roland Wakieć,<sup>1</sup> Iwona Gabriel,<sup>1</sup> Rajendra Prasad,<sup>2</sup> Jeffrey M. Becker,<sup>3</sup>  
John W. Payne,<sup>4</sup> and Sławomir Milewski<sup>1\*</sup>

Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, 11/12 Narutowicza Street, 80-952 Gdańsk, Poland<sup>1</sup>; Membrane Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India<sup>2</sup>; Department of Microbiology, University of Tennessee, Knoxville, Tennessee<sup>3</sup>; and School of Biological Sciences, University of Wales, Bangor, Wales, United Kingdom<sup>4</sup>

Received 21 December 2007/Returned for modification 9 February 2008/Accepted 7 September 2008

**The susceptibility to several oligopeptide and amino acid antifungals of a *Saccharomyces cerevisiae* strain carrying multiple deletions in yeast multidrug resistance genes was compared to transformants containing the *CDR1*, *CDR2*, or *MDR1* genes that encode the major *Candida albicans* drug efflux pumps. Recombinant yeast strains overexpressing Cdr1p and Cdr2p showed enhanced susceptibilities to all tested oligopeptide antifungals. The enhanced susceptibilities of multidrug-resistant yeast strains to oligopeptide antifungals corresponded to higher rates of oligopeptide uptake. Yeast cells overexpressing Cdr1p or Cdr2p effluxed protons at higher rates than the reference cells lacking these ABC transporters. An increased plasma membrane electrochemical gradient caused by the functional overexpression of Cdr1p or Cdr2p appeared to increase cellular susceptibility to oligopeptide antifungals by stimulating their uptake via oligopeptide permeases.**

The frequency of fungal infections in immunocompromised patients and mortality due to invasive mycoses continue to be important clinical problems, and opportunistically pathogenic *Candida* species remain one of the leading causes of nosocomial bloodstream infections worldwide (13, 31, 35). *Candida albicans* comprises nearly half of the isolates of candidemia (44). The repertoire of antifungal chemotherapeutic agents is very limited, and although new antifungal drugs, such as voriconazole and caspofungin, have been introduced into clinical practice in recent years, the development of resistance, often multidrug resistance (MDR), has become increasingly significant (23).

The molecular mechanism underlying MDR is overexpression of membrane proteins belonging to members of a family of ATP-binding cassette (ABC) transporters or the major facilitator superfamily. In *Candida albicans*, Cdr1p and Cdr2p were identified as the major ABC drug transporters, while CaMdr1p and FLU1p are the main representatives of the major facilitator superfamily (36). The substrate specificity spectrum of fungal MDR transporters includes many therapeutically important antifungal drugs, including azole antifungals (40). The development of the MDR phenotype in *C. albicans* clinical strains isolated from patients subjected to antifungal chemotherapy with fluconazole is a well-documented phenomenon (1, 10, 11), and fluconazole is widely used for antifungal prophylaxis in immunocompromised patients (31). There is a need for new antifungals that circumvent MDR.

It was previously shown that recombinant yeast cells overexpressing the *C. albicans* Cdr1p drug efflux pump were

paradoxically more susceptible to the action of oligopeptidic antifungal agents containing *N*<sup>3</sup>-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP). It was suggested that the observed hypersusceptibility might be due to the increased uptake of FMDP peptides mediated by oligopeptide permeases (27). In the present study, the effects of several structurally unrelated antifungal oligopeptides and amino acids were investigated in MDR clinical isolates of *Candida albicans* and genetically modified strains of the model yeast *Saccharomyces cerevisiae* that overexpress genes encoding *C. albicans* Cdr1p, Cdr2p, or Mdr1p drug efflux pumps.

### MATERIALS AND METHODS

**Chemicals.** Nva-FMDP and Lys-Nva-FMDP were synthesized by R. Andruszkiewicz (3). Methods for the synthesis of oligopeptides containing oxalysine (OLys), *m*-fluorophenylalanine (FPhe), or 5-fluoroorotic acid were described previously (4, 21, 43). Nikkomycin X/Z was a gift from H. Zähler, University of Tübingen, Germany. Fluconazole was from Pliva Krakow (Cracow, Poland). Histatin 5 (DSHAKRHHGYKRKFHEKHSHRGY) and other chemicals were from Sigma or Calbiochem.

**Yeast strains and growth conditions.** The yeast strains used in this investigation are presented in Table 1. *S. cerevisiae* AD12345678 (hereafter denoted strain AD) was kindly provided by A. Goffeau, Université Catholique de Louvain, Belgium. The AD-derived MDR cells were obtained by previously described methods (14, 37, 42). The AD cells were propagated in yeast-nitrogen base-glucose (YNBG) medium containing 0.67% YNB without amino acids and ammonium sulfate (Difco), 2% glucose, and 4 mg/ml of L-proline (or, if indicated, 1 mg/ml of L-glutamate) supplemented with L-histidine at 40 µg/ml and uracil at 30 µg/ml, while the AD-derived transformants were maintained in a similar medium lacking uracil. *C. albicans* cells were propagated in 2% glucose, 1% yeast extract, 1% Bacto peptone medium. *C. albicans* B3, B4, Gu4, and Gu5 clinical isolates were kindly provided by Joachim Morschhäuser, Würzburg, Germany. Gu4 and B3 are fluconazole-sensitive isolates obtained from early infection episodes, while Gu5 and B4 are the corresponding fluconazole-resistant isolates obtained from later episodes in the same patients treated with fluconazole (10). For each sensitive/resistant pair, comparison of CARE-2 fingerprint hybridization patterns confirmed that a single strain was responsible for the recurrent infection. Reverse transcription-PCR, Northern blotting, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the plasma mem-

\* Corresponding author. Mailing address: Department of Pharmaceutical Technology & Biochemistry, Gdańsk University of Technology, 11/12 Narutowicza St., 80-952 Gdańsk, Poland. Phone: 48 583472107. Fax: 48 583471144. E-mail: milewski@altis.chem.pg.gda.pl.

<sup>∇</sup> Published ahead of print on 15 September 2008.

TABLE 1. Microbial strains used in this study

Strain	Description	Source or reference
<i>S. cerevisiae</i> ATCC 9763	Wild type	ATCC
<i>S. cerevisiae</i> AD12345678	<i>MAT<math>\alpha</math> pdr1-3 his ura3 pdr5<math>\Delta</math> snq2<math>\Delta</math> pdr10<math>\Delta</math> pdr11<math>\Delta</math> pdr15<math>\Delta</math> yor1<math>\Delta</math> ycf1<math>\Delta</math></i>	9
<i>S. cerevisiae</i> ADCDR1	AD12345678 transformed with <i>CDR1</i>	42
<i>S. cerevisiae</i> ADCDR2	AD12345678 transformed with <i>CDR2</i>	42
<i>S. cerevisiae</i> ADMDR1	AD12345678 transformed with <i>MDR1</i>	14
<i>C. albicans</i> ATCC 10261	Wild type	ATCC
<i>C. albicans</i> Gu4	Clinical isolate (fluconazole sensitive)	11
<i>C. albicans</i> Gu5	Clinical isolate (fluconazole resistant due to the overexpression of <i>CDR1</i> and <i>CDR2</i> )	11
<i>C. albicans</i> B3	Clinical isolate (fluconazole sensitive)	11
<i>C. albicans</i> B4	Clinical isolate (fluconazole resistant due to the overexpression of <i>MDR1</i> )	11

brane preparations indicated the molecular basis of the phenotypes ascribed in Table 1.

**Susceptibility testing methods.** MICs of antifungals were determined by the microdilution methods using 96-well microtiter plates. MICs for *C. albicans* clinical isolates were determined in RPMI-1640 medium using the CLSI M27-A2 document recommendations (30). For *S. cerevisiae* recombinants, most conditions were the same, but an appropriately supplemented YNBG medium (see above) was used, and incubation was for 24 h at 30°C. Turbidity in individual wells was measured with a plate reader (Victor<sup>3</sup>; PerkinElmer). MIC was defined as a drug concentration that gave at least an 80% decrease in turbidity relative to that of the drug-free growth control.

**Determination of peptide and amino acid uptake rates.** Initial velocities of oligopeptide or amino acid uptake were determined using a modification of the method of Payne and Nisbet (32). Yeast cells grown in the YNBG-proline medium were harvested, washed, and suspended in 50 mM phosphate-citrate buffer, pH 6.0, containing 1% glucose, to a final optical density at 660 nm ( $OD_{660}$ ) of 1.0. The cell suspension was preincubated for 10 min at 30°C, and a peptide or amino acid solution was added to give the final concentration of 50  $\mu$ M. In some experiments, 100  $\mu$ M fluconazole was added at the beginning of the preincubation. Suspensions supplemented with 10 mM  $NaN_3$  were used as negative controls to correct for the background passive binding of each oligopeptide/amino acid to the cells. A suspension without an oligopeptide/amino acid was used as a blank. Samples of 1 ml of cell suspension, withdrawn at zero time and at 5-min intervals, were filtered through Whatman GF/C filters. Samples of 200  $\mu$ l from each filtrate were combined with 2-ml portions of 0.1 M tetraborate-HCl buffer, pH 6.2 (oligopeptide uptake determination) or pH 8.4 (amino acid uptake determination). Fluorescamine in acetone (0.15 mg/ml and 500  $\mu$ l) was added, and the resulting fluorescence intensities were measured (excitation, 390 nm; emission, 485 nm). Initial uptake rates were determined from the plots of the oligopeptide/amino acid remaining versus time. Standard curves were generated for each oligopeptide and amino acid after dissolution in the appropriate tetraborate-HCl buffer and treatment with fluorescamine.

**Efflux of oligopeptides and amino acids from yeast cells.** AD, ADCDR1, or ADCDR2 cells were grown in YNBG to the logarithmic phase of growth, harvested, washed three times in water, and resuspended to an  $OD_{660}$  of 1.0 in 50 mM phosphate buffer, pH 6.0, containing 5 mM 2-deoxy-D-glucose (2DG). Cell suspensions were incubated for 2 h at 30°C with gentle shaking, and the cells were harvested, washed three times in water, and resuspended in 50 mM phosphate-citrate buffer, pH 4.0. Amino acids or oligopeptides (200  $\mu$ M) were added, and the cell suspensions were incubated for 60 min at 30°C with gentle shaking. Samples of the cell suspensions were collected at 10-min time intervals to monitor amino acid/oligopeptide uptake by the fluorescamine method (see above). Amino acid/oligopeptide-loaded cells were harvested, washed two times in water, and resuspended at an  $OD_{660}$  of 1.0 in prewarmed (30°C) 50 mM phosphate buffer, pH 6.0. After a 5-min preincubation, glucose (10 mM) was added and cell suspensions were incubated at 30°C with gentle shaking. Culture supernatants were collected at 5-min time intervals to monitor the appearance of effluxed amino acid/oligopeptide by the fluorescamine method. Yeast cell cultures treated as above, except for loading with an amino acid/oligopeptide, were used as a negative control to detect a background level of any fluorescamine-reactive compounds extruded by the cells. In separate experiments, cells deenergized by incubation with 2DG were loaded with rhodamine 6G (10  $\mu$ M) instead of an amino acid/oligopeptide. An active glucose-dependent extrusion of the dye was measured as described previously (45).

**Other methods.** Amino acids released from the oligopeptides by hydrolytic enzymes present in cell extracts from the yeast cells were quantified using the

Cd-ninhydrin method (28). Intracellular pH was determined by the method of Bracey et al. with 5(6)-carboxyfluorescein diacetate-succinimidyl ester (CFDA-SE) as a fluorescent probe (7). The initial rates of proton efflux were determined as described previously (18).

## RESULTS

**Microorganisms used in the study.** This study used as a model system the recombinant *S. cerevisiae* AD strain, deleted of seven MDR transporters (9), and its transformants overexpressing either *CDR1*, *CDR2*, or *MDR1* genes encoding the major drug effluxing pumps of *C. albicans*. In all transformants, each gene of interest was expressed from the centromeric pYEura3 plasmid under the control of its natural promoter (14, 42). *C. albicans* clinical isolates that developed resistance to fluconazole during antifungal chemotherapy with this drug were also tested. The resistance of isolates Gu5 and B4 is due to the documented overexpression of *CDR1* and/or *CDR2* in the former and *MDR1* in the latter (10, 11). Their matched fluconazole-sensitive isolates Gu4 and B3, respectively, exhibited basal expression of these resistance genes.

**Growth inhibition of MDR yeast by oligopeptide and amino acid antifungals.** The in vitro susceptibilities of the strains described above to several antifungal oligopeptides and amino acids were determined. A set of the antifungal peptides included the following: 5-FO-L-leucyl-L-leucine 1, three oligopeptides incorporating OLys 2 to 4, a dipeptide and a tripeptide incorporating FPhe 5 and 6, two oligopeptides containing FMDP 7 and 8, the peptide-nucleoside antibiotic nikkomycin X/Z 9, and a human salivary polypeptide histatin 5. A set of the antifungal amino acids included the following: L-Asp- $\gamma$ -hydroxamate 10, OLys 11, FPhe 12, *cis*-pentacin 13, 6-diazo-5-oxo-L-norleucine (DON) 14, and azaserine 15 (Fig. 1). Fluconazole was included as a reference to confirm the susceptibility/resistance of each strain.




FIG. 1. Structures of amino acid antifungals 10 to 15 used in this study.

TABLE 2. In vitro fungistatic activities of oligopeptide antifungals and fluconazole against *S. cerevisiae* reference and recombinant strains

Oligopeptide	MIC (µg/ml) of <sup>a</sup> :				
	ATCC 9763	AD	ADCDR1	ADCDR2	ADMDR1
SFO-Leu-Leu (1)	512	512	128	256	512
OLys-Leu-Gly (2)	8	4	1	1	4
OLys-Leu-Leu-Gly (3)	64	64	16	32	64
OLys-Leu-Leu-Leu-Gly (4)	256	256	128	128	256
Leu-FPhe (5)	256	256	8	4	256
Met-Met-FPhe (6)	256	512	32	32	256
Nva-FMDP (7)	4	4	0.5	1	4
Lys-Nva-FMDP (8)	32	32	4	8	32
Nikkomycin (9)	128	128	16	16	128
Histatin 5	128	128	128	128	128
Fluconazole	2	1	32	16	32

<sup>a</sup> MICs were determined as described in Materials and Methods by the microtiter serial twofold dilution method using the YNBG-proline medium containing 2% glucose. Inoculum size was 10<sup>5</sup> CFU/ml. Plates were incubated for 24 h at 30°C.

The results of the determination of antifungal in vitro activities of oligopeptidic antifungals against the *S. cerevisiae* strains are shown in Table 2. The yeast MDR genes disrupted in AD cells did not significantly change the strain's drug susceptibility profile, in comparison to the control ATCC 9763 strain, apart from a barely detectable increase in sensitivity to fluconazole. The ADCDR1, ADCDR2, and ADMDR1 strains were much less susceptible to fluconazole than AD. In contrast, the ADCDR1 and ADCDR2 strains showed enhanced susceptibilities to several oligopeptide antifungals. The strongest effects, reflected in the AD MIC/ADCDR1 MIC or AD MIC/ADCDR2 MIC ratios in the 64-fold/8-fold range, were observed for Leu-FPhe, Met-Met-FPhe, Nva-FMDP, Lys-Nva-FMDP, and nikkomycin. For other oligopeptides, the MIC ratios were in the two- to fourfold range. The ADMDR1 transformant showed an oligopeptide antifungal susceptibility comparable to that of the parent AD strain, despite a marked increase in resistance to fluconazole. A salivary polypeptide histatin 5 showed comparable activity against all strains.

The results of the determination of growth inhibitory activities of antifungal amino acids presented in Table 3 showed a few cases of slightly different susceptibilities of the MDR

TABLE 3. In vitro fungistatic activities of amino acid antifungals against *S. cerevisiae* reference and recombinant strains

Amino acid	MIC(s) (µg/ml) of <sup>a</sup> :				
	ATCC 9763	AD	ADCDR1	ADCDR2	ADMDR1
Asp-γ-hydroxamate (10)	256	256	64	64	128
OLys (11)	8	8	2	4	16
FPhe (12)	32	32	16	16	32
cis-pentacin (13)	64, 4 <sup>b</sup>	128, 8 <sup>b</sup>	256, 16 <sup>b</sup>	256, 16 <sup>b</sup>	256, 16 <sup>b</sup>
DON (14)	0.5	0.5	0.125	0.25	0.5
Azaserine (15)	2	2	1	1	2

<sup>a</sup> MIC(s) determined under conditions described in Table 2.

<sup>b</sup> MICs determined by using the YNBG medium containing 1 mg/ml of l-glutamate instead of l-proline as the main nitrogen source.

TABLE 4. In vitro susceptibilities of *Candida albicans* reference strain and clinical isolates to oligopeptide and amino acid antifungals and fluconazole

Compound	MIC (µg/ml) of <sup>a</sup> :				
	ATCC 10261	Gu4	Gu5 ( <i>CDR1</i> and/or <i>CDR2</i> )	B3	B4 ( <i>MDR1</i> )
OLys-Leu-Gly (2)	128	256	16	64	32
Leu-FPhe (5)	64	128	8	64	64
Met-Met-FPhe (6)	128	128	32	128	128
Nva-FMDP (7)	2	2	0.125	4	4
Lys-Nva-FMDP (8)	8	4	1	8	8
Nikkomycin (9)	32	16	4	8	8
Histatin 5	32	32	32	32	32
Asp-γ-hydroxamate (10)	256	256	128	256	256
OLys (11)	16	16	4	16	32
FPhe (12)	256	128	128	128	128
cis-pentacin (13)	1	1	4	2	8
DON (14)	4	4	1	4	4
Azaserine (15)	16	16	16	32	32
Fluconazole	4	8	256	4	64

<sup>a</sup> MICs were determined by using RPMI-1640 buffered medium, as described in Materials and Methods. No growth inhibition was observed for oligopeptides 1, 3, and 4 at a concentration of ≤1,024 µg/ml.

strains to L-Asp-γ-hydroxamate, FPhe, OLys, DON, and azaserine. FPhe, OLys, DON, and azaserine were only slightly more active (two- to fourfold) against ADCDR1 and ADCDR2 cells than against the parent AD strain. All MDR transformants showed decreased susceptibilities to cis-pentacin.

MICs of antifungal amino acids, oligopeptides, and fluconazole against *C. albicans* clinical isolates Gu4 and B3, presented in Table 4, were similar to those found for the reference ATCC 10261 strain. Strains Gu5 and B4 were strongly resistant to fluconazole. Compared with Gu4, Gu5 cells overexpressing *CDR1* and/or *CDR2* showed enhanced susceptibilities to oligopeptides 2 and 5 to 9. Gu4 MIC/Gu5 MIC ratios were in the 4- to 16-fold range, and the highest values were found for OLys-Leu-Gly and Leu-FPhe. In B4, overexpression of *MDR1* had little or no effect on the susceptibilities of *C. albicans* cells to oligopeptides 2 and 5 to 9 and amino acid antifungals 10 to 12, 14, and 15. All *C. albicans* strains were equally susceptible to histatin 5. Gu5 cells were slightly more susceptible to OLys 11 and DON 14 than the Gu4 cells. No differences were found for FPhe and azaserine. The MDR strains Gu5 and B4 were less susceptible to cis-pentacin 13 than their parental strains.

**Uptake of amino acid and oligopeptide antifungals by MDR yeast cells and intracellular processing of oligopeptides.** The antifungal action of all oligopeptide and amino acid antifungals used in this study is antagonized by proteinogenic oligopeptides or amino acids, respectively, which compete for uptake into the fungal cells via oligopeptide or amino acid permeases (4, 8, 21, 26, 28, 43, 46, 47). To test whether the presence and activity of drug-effluxing transporters affected oligopeptide or amino acid transport, the uptake rates of these compounds, alanine, Ala-Ala, and Ala-Ala-Ala, were determined.

The uptake rates of oligopeptides and amino acids tested were constant for at least 15 to 20 min and then gradually decreased. These properties allowed the determination of initial uptake velocities. The rates were corrected for passive

TABLE 5. Initial rates of oligopeptide uptake by yeast mutants

Oligopeptide	Initial transport rate (nmol/min/mg dry wt) $\pm$ SD of <sup>a</sup> :			
	AD	ADCDR1	ADCDR2	ADMDR1
Ala-Ala	2.55 $\pm$ 0.38 <sup>b</sup>	4.20 $\pm$ 0.47 <sup>b</sup>	3.94 $\pm$ 0.50 <sup>b</sup>	2.61 $\pm$ 0.35 <sup>b</sup>
	2.58 $\pm$ 0.32	4.46 $\pm$ 0.51	4.08 $\pm$ 0.44	2.59 $\pm$ 0.33
Ala-Ala-Ala	3.15 $\pm$ 0.45	5.30 $\pm$ 0.57	4.74 $\pm$ 0.60	2.91 $\pm$ 0.25
OLys-Leu-Gly (2)	0.70 $\pm$ 0.07 <sup>b</sup>	1.32 $\pm$ 0.06 <sup>b</sup>	1.26 $\pm$ 0.08 <sup>b</sup>	0.85 $\pm$ 0.08 <sup>b</sup>
	0.69 $\pm$ 0.08	1.42 $\pm$ 0.09	1.31 $\pm$ 0.10	0.87 $\pm$ 0.06
OLys-Leu-Leu-Gly (3)	0.51 $\pm$ 0.18	0.83 $\pm$ 0.16	0.96 $\pm$ 0.12	0.65 $\pm$ 0.08
OLys-Leu-Leu-Leu-Gly (4)	0.31 $\pm$ 0.12	0.49 $\pm$ 0.13	0.51 $\pm$ 0.11	0.28 $\pm$ 0.08
Leu-FPhe (5)	0.79 $\pm$ 0.08 <sup>b</sup>	1.82 $\pm$ 0.04 <sup>b</sup>	2.23 $\pm$ 0.12 <sup>b</sup>	0.87 $\pm$ 0.11 <sup>b</sup>
	0.79 $\pm$ 0.07	1.95 $\pm$ 0.11	2.37 $\pm$ 0.21	0.84 $\pm$ 0.09
Met-Met-FPhe (6)	0.64 $\pm$ 0.09	1.11 $\pm$ 0.14	1.23 $\pm$ 0.16	0.67 $\pm$ 0.10
Nva-FMDP (7)	0.96 $\pm$ 0.09	1.86 $\pm$ 0.11	1.56 $\pm$ 0.13	1.02 $\pm$ 0.10
Lys-Nva-FMDP (8)	0.79 $\pm$ 0.05	1.61 $\pm$ 0.12	1.18 $\pm$ 0.09	0.81 $\pm$ 0.09
Nikkomycin (9)	0.32 $\pm$ 0.02 <sup>b</sup>	0.98 $\pm$ 0.03 <sup>b</sup>	0.88 $\pm$ 0.06 <sup>b</sup>	0.34 $\pm$ 0.04 <sup>b</sup>
	0.33 $\pm$ 0.05	1.08 $\pm$ 0.08	0.97 $\pm$ 0.08	0.32 $\pm$ 0.05

<sup>a</sup> Initial uptake rates were determined as described in Materials and Methods. Values are the means of three determinations  $\pm$  the standard deviation (SD).

<sup>b</sup> Cells were pretreated with fluconazole for 10 min.

binding of the compounds tested by measuring uptake in the presence of NaN<sub>3</sub>, accounting for less than 3% of the initial rate of oligopeptide/amino acid uptake.

The results of the determination of the initial uptake rates of compounds 1 to 9 and the model (Ala)<sub>2</sub> and (Ala)<sub>3</sub> oligopeptides are presented in Table 5. The initial uptake rates of compounds 1 to 9 into AD cells were in each case lower than those of the alanyl oligopeptides, but the ADCDR1 and ADCDR2 cells took up all the oligopeptides tested 1.5- to 3-fold faster than the AD strain. Uptake rates for the ADMDR1 strain were virtually identical to those of the AD strain. A 10-min pretreatment with fluconazole of ADCDR1 and ADCDR2 cells, but not AD or ADMDR1 cells, enhanced by up to 10% the uptake of Ala-Ala and the oligopeptide antifungals OLys-Leu-Gly, Leu-FPhe, and nikkomycin. Histatin 5 was taken up slowly (0.6  $\pm$  0.05 nmol/min/mg dry weight) by all strains, but there was no substantial difference between AD and AD-derived cells. A comparison of Tables 5 and 2 suggests that all cases of increased transport rates of oligopeptide antifungals correlated with enhanced susceptibilities of MDR cells to these compounds. There was no direct correlation between susceptibilities (Table 3) and uptake rates (Table 6) for amino acid antifungals.

Antifungal action of oligopeptides 1 to 8 requires intracellular cleavage to release an active enzyme inhibitor. The rate of this cleavage could affect the antifungal activity of oligopeptides. The cleavage rates obtained for cell extracts prepared

from ATCC 9763, AD, ADCDR1, ADCDR2, and ADMDR1 cells were all within the 14 to 25 nmol/min/mg protein range (data not shown). There was no statistically significant difference between the cleavage rates for a particular oligopeptide determined in extracts from cells lacking or overexpressing MDR transporters. These measurements indicated that intracellular cleavage did not limit the activities of oligopeptide antifungals 1 to 8. Nikkomycin 9 and histatin 5 were very slowly cleaved (the rates were 0.4 to 0.5 and 0.1 to 0.15 nmol/min/mg protein, respectively); however, both of these agents act on the targets in an intact form (15, 46). The cleavage rates determined for *C. albicans* ATCC 10261, Gu4, Gu5, B3, and B4 cells were slightly higher (20 to 32 nmol/min/mg protein for compounds 1 to 8 and 0.3 to 0.8 nmol/min/mg protein for nikkomycin and histatin 5), and there was no significant difference between MDR and sensitive strains.

**Changes in intra- and extracellular pH in MDR yeast strains.** We previously found that yeast mutants overexpressing *CDR1* had demonstrated enhanced proton-extruding activity (27). To test if the enhanced rates of uptake of oligopeptides and amino acids in cells overexpressing *CDR1* and/or *CDR2* might result from modifications of plasma membrane electrochemical potential, the intracellular pH and the rates of glucose-dependent proton efflux were measured. The intracellular pH was monitored using CFDA-SE as a fluorescent probe. The results of this experiment, presented in Fig. 2, show that probe-loaded, glucose-deprived yeast cells maintain an intracellular pH in the range of 5.4 to 5.6. This relatively low intracellular pH, compared with that determined in other studies (7, 20), may be due to the deactivation of the plasma membrane H<sup>+</sup>-ATPase, Pma1p (2), at a low pH in the absence of glucose (43). The glucose addition, while only slightly increasing the intracellular pH of the AD and ADMDR1 cells, markedly increased the intracellular pHs of ADCDR1 and ADCDR2 cells. Subsequent addition of fluconazole further alkalinized the cytoplasm of ADCDR1 and ADCDR2 cells, but the intracellular pHs of AD and ADMDR1 remained essentially unchanged. The addition of fluconazole without a prior glucose addition did not significantly increase the intra-

TABLE 6. Initial rates of amino acid uptake by yeast mutants

Amino acid	Initial transport rate (nmol/min/mg dry wt) $\pm$ SD of <sup>a</sup> :			
	AD	ADCDR1	ADCDR2	ADMDR1
Ala	3.51 $\pm$ 0.56	4.16 $\pm$ 0.38	4.35 $\pm$ 0.41	3.33 $\pm$ 0.33
Asp- $\gamma$ -hydroxamate (10)	1.54 $\pm$ 0.16	2.25 $\pm$ 0.42	1.69 $\pm$ 0.11	1.25 $\pm$ 0.13
FPhe (11)	1.48 $\pm$ 0.16	1.81 $\pm$ 0.18	1.44 $\pm$ 0.12	1.36 $\pm$ 0.15
OLys (12)	1.78 $\pm$ 0.11	2.57 $\pm$ 0.15	1.86 $\pm$ 0.06	1.63 $\pm$ 0.07
Cispenitacin (13)	1.63 $\pm$ 0.20	2.11 $\pm$ 0.21	1.85 $\pm$ 0.16	1.67 $\pm$ 0.18
DON (14)	2.0 $\pm$ 0.22	2.32 $\pm$ 0.31	2.25 $\pm$ 0.16	1.98 $\pm$ 0.19
Azaserine (15)	1.75 $\pm$ 0.23	2.15 $\pm$ 0.17	1.92 $\pm$ 0.22	1.70 $\pm$ 0.17

<sup>a</sup> Conditions of the determination were as described in Table 5. Values are the means of three determinations  $\pm$  the standard deviation (SD).




FIG. 2. Changes in the intracellular pH of yeast cells caused by glucose and fluconazole addition. Yeast cells suspended in a buffer at pH 4.0 were starved of glucose and loaded with CFDA-SE. Cells were then suspended in buffer, pH 4.5, and treated with glucose and fluconazole. Samples were collected at time intervals, and fluorescence at excitation of 435 and 495 nm ( $F_{495}$  and  $F_{435}$ ) was measured at 525 nm.  $F_{495}$  and  $F_{435}$  ratios were used to calculate the intracellular pH values.

cellular pH. Thus, metabolic energy is needed for fluconazole-induced enhancement of intracellular pH.

Glucose-dependent proton efflux was monitored in unbuffered cell suspensions adjusted to pH  $5.2 \pm 0.05$  (Fig. 3). The ADCDR1 and ADCDR2 cells extruded protons 1.5 to 2-fold more rapidly than the AD or ADMDR1 cells. These results confirm previous observations made for the *CDR1*-containing transformants (27) and indicate that overexpression of Cdr1p or Cdr2p causes similar effects. The same phenomenon was observed for *C. albicans* clinical isolates overexpressing *CDR1* and *CDR2* but not *MDR1*. Vanadate, an inhibitor of the in vitro ATPase activity of the fungal Pma1p and ABC transporters (6), partially inhibited proton efflux in all types of cells tested.

The differences in glucose-dependent internal pH and glucose-dependent proton pumping between the cells overexpressing the ABC transporters and the control and ADMDR1 strains suggested that overexpression of ABC transporters increased the plasma membrane electrochemical potential. The susceptibilities of yeast cells to the protein synthesis inhibitor hygromycin B are pH dependent, and resistance has been correlated with depolarization of the plasma membrane in *pma1* mutants (33). The antifungal activity of hygromycin B was determined for mutant yeast cells used in this study. The hygromycin MICs were as follows: 128, 64, 32, and 128  $\mu\text{g/ml}$  for the AD, ADCDR1, ADCDR2, and ADMDR1 cells, respectively.

**Oligopeptides and amino acids are not substrates for Cdr1p and Cdr2p.** Cells deenergized with 2DG and suspended in buffer (pH 4.0) were loaded with an amino acid or oligopeptide and then reenergized by a glucose addition at pH 6.0, thus triggering possible efflux. Cdr1p and Cdr2p functionality in the reenergized cells was confirmed using rhodamine 6G as a probe. During the 60-min loading, the cells accumulated 32 to 67% of each amino acid/oligopeptide. No fluorescamine-positive compounds were detected in spent medium samples collected from the AD, ADCDR1, and ADCDR2 cell suspensions loaded with most of the antifungal compounds tested and reenergized with glucose at pH 6.0. The only exception was the




FIG. 3. Initial rates of proton efflux by yeast mutants. The rates were determined by monitoring pH changes of yeast cell suspensions. Cells were transferred from the minimal growth medium to unbuffered water, and pH changes were recorded after glucose addition. Each bar represents the mean of three independent determinations  $\pm$  the standard deviation (SD).

extrusion of *cis*-pentacin 13 from the ADCDR1 and ADCDR2 cells ( $5 \pm 2 \mu\text{M}$  of the fluorescamine-*cis*-pentacin conjugate was detected after 30 min). These results show that all oligopeptides and amino acids tested, except *cis*-pentacin, are not extruded by Cdr1p and Cdr2p.

## DISCUSSION

MDR yeast strains overexpressing *CDR1* show strikingly increased susceptibilities to antifungal FMDP oligopeptides (27). The present work has shown that recombinant yeast and clinical *C. albicans* isolates overexpressing *CDR1* and/or *CDR2* genes are more susceptible to several different antifungal oligopeptides than their respective parental strains lacking these genes or expressing them at the basal level. On the other hand, yeast strains overexpressing the *MDR1* gene showed susceptibilities to all oligopeptides similar to those of their parental strains. The enhanced susceptibilities to numerous oligopeptide antifungals, which represent a broad range of structures and mechanisms of antifungal action, appear to be a feature of MDR yeast strains overexpressing the Cdr1p and Cdr2p ABC drug transporters.

We suggest that the enhanced susceptibility of MDR yeast strains to oligopeptide antifungals is due to enhanced oligopeptide antifungal uptake mediated by oligopeptide permeases that are affected by an increased membrane potential induced by overexpression of the ABC drug efflux pumps Cdr1p and Cdr2p. In yeast strains, the inward transport of oligopeptides containing two to eight amino acid residues is exclusively mediated by active transport systems involving permeases acting as ligand/ $\text{H}^+$  symporters (16, 34, 39). In contrast, and consistent with our observations, relatively large antifungal polypeptides, like histatin 5, are internalized in an energy-dependent manner via cell wall-located receptors (24), while compounds known as the "cell-penetrating peptides" cross the membrane by free diffusion (17). The presence of the peptide permeases makes the yeast cells susceptible to the action of oligopeptide antifungals targeting intracellular enzymes. Some of these compounds, including nikkomycin 9, attack their targets in an intact form (46). Other oligopeptides,

like compounds 1 to 8, are cleaved intracellularly by peptidases, and the released enzyme inhibitor is then able to reach its target (3, 4, 21, 28, 29, 43). The uptake of antifungal oligopeptides, rather than their intracellular cleavage, appears to be the rate-limiting step that determines their potency (25, 26). Thus, the relatively slow accumulation of oligopeptides 1 to 9 by the AD cells, a substantial enhancement of this uptake in AD-derived mutants overexpressing *CDR1* or *CDR2* and a good match between the enhanced transport rates and the increased antifungal activity, are consistent with the enhanced susceptibilities to oligopeptide antifungals being due to accelerated uptake.

The enhanced rates of glucose-dependent proton efflux and the fluconazole-stimulated alkalinization of the cytoplasm suggested that the overexpression of the ABC transporters Cdr1p and Cdr2p increased the membrane potential associated with the yeast plasma membrane. This concept was confirmed by demonstrating the enhanced susceptibilities of ADCDR1 and ADCDR2 cells to hygromycin B. Consistent with a mechanism in which the additional proton motive force drives proton gradient-dependent oligopeptide permeases, yeast isolate susceptibility to histatin 5 was not increased in cells overexpressing these two ABC transporters. The observed faster accumulation of amino acids by ADCDR1 and ADCDR2 was also most likely due to the increased membrane potential, since these compounds are transported into yeast cells by proton motive force-dependent permeases (5, 19, 38).

The molecular basis of pH changes observed in yeast cells expressing the ABC drug transporters has yet to be explained. They may result from a disturbance of physical properties of the cell membrane or be due to stimulation of proton export mediated by ABC drug transporters or other membrane proteins. The transmembrane proton gradient in yeast cells is normally maintained by the vanadate-sensitive plasma membrane proton pump Pma1p (2, 41). In this study, proton efflux was partially inhibited by vanadate in all cell types. Vanadate inhibits the ATP hydrolytic activity of both ABC transporters and Pma1p in plasma membrane preparations (22), but its effects on these activities in whole cells are not known. Nevertheless, stimulation of Pma1p activity due to the changes in membrane properties cannot be excluded. Another possibility is proton-effluxing activities of Cdr1p and Cdr2p, similar to those of human Mdr1p expressed in *S. cerevisiae*, found by Fritz et al. (12). This possibility may be supported by the fact that fluconazole efflux in ADCDR1 and ADCDR2 cells gave stronger alkalinization to the cytoplasm and a higher uptake rate of oligopeptide antifungals. It may be possible as well that the observed higher glucose-induced internal alkalinization of ADCDR1 and ADCDR2 cells was due to Cdr1p or Cdr2p proton-effluxing activity, since those cells were prestarved under conditions ensuring deactivation of Pma1p. Further studies are necessary to explore and exploit the possibilities. Nevertheless, we conclude that the phenomenon of the enhanced susceptibilities of yeast cells overexpressing the ABC-type MDR transporters to a broad range of oligopeptidic antifungals results from an accelerated uptake driven by an additional proton motive force created in these cells.

## ACKNOWLEDGMENTS

This work was supported by the Polish Ministry of Science and Higher Education Grant no. 3 P05F 023 24.

We thank Gillian Payne and Izabela Łacka for their help in some experiments. The generous gift of strains from Joachim Morschhäuser is gratefully acknowledged.

## REFERENCES

- Albertson, G. D., M. Niimi, and R. D. Cannon. 1996. Multiple efflux mechanisms are involved in *Candida albicans* fluconazole resistance. *Antimicrob. Agents Chemother.* **40**:2835–2841.
- Ambesi, A., M. Miranda, V. V. Petrov, and C. W. Slayman. 2000. Biogenesis and function of the yeast plasma membrane H<sup>+</sup>-ATPase. *J. Exp. Biol.* **203**:155–160.
- Andruszkiewicz, R., S. Milewski, T. Zieniawa, and E. Borowski. 1990. Anticandidal properties of N<sup>3</sup>-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid oligopeptides. *J. Med. Chem.* **33**:132–135.
- Basrai, M. A., H. L. Zhang, D. Miller, F. Naider, and J. M. Becker. 1992. Toxicity of oxalysine and oxalysine-containing peptides against *Candida albicans*: regulation of peptide transport by amino acids. *J. Gen. Microbiol.* **138**:2353–2362.
- Biswas, S., M. Roy, and A. Datta. 2003. N-acetylglucosamine-inducible CaGAP1 encodes a general amino acid permease which co-ordinates external nitrogen source response and morphogenesis in *Candida albicans*. *Microbiology* **149**:2597–2608.
- Bowman, B. J., and C. W. Slayman. 1979. The effect of vanadate on the plasma membrane ATPase of *Neurospora crassa*. *J. Biol. Chem.* **254**:2928–2934.
- Bracey, D., C. D. Holyoak, G. Nebe-von Caron, and P. J. Coote. 1998. Determination of the intracellular pH (pH<sub>i</sub>) of growing cells of *Saccharomyces cerevisiae*: the effect of reduced-expression of the membrane H<sup>+</sup>-ATPase. *J. Microbiol. Methods* **31**:113–125.
- Capobianco, J. O., D. Zakula, M. N. Coen, and R. C. Goldman. 1993. Anti-*Candida* activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. *Biochem. Biophys. Res. Commun.* **190**:1037–1042.
- Decottignies, A., A. M. Grant, J. W. Nichols, H. de Wet, D. B. McIntosh, and A. Goffeau. 1998. ATP-ase and multidrug transport activities of overexpressed yeast ABC protein Yor1p. *J. Biol. Chem.* **273**:12612–12622.
- Franz, R., M. Ruhnke, and J. Morschhäuser. 1999. Molecular aspects of fluconazole resistance development in *Candida albicans*. *Mycoses* **42**:453–458.
- Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains. *Antimicrob. Agents Chemother.* **42**:3065–3072.
- Fritz, F., E. M. Howard, M. M. Hoffman, and P. D. Roepe. 1999. Evidence for altered ion transport in *Saccharomyces cerevisiae* overexpressing human MDR1 protein. *Biochemistry* **38**:4214–4226.
- Gudlaugsson, O., S. Gillespie, K. Lee, J. Van de Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia. *Clin. Infect. Dis.* **37**:1172–1177.
- Gupta, V., A. Kohli, S. Krishnamurthy, N. Puri, S. A. Aalamgeer, S. Panwar, and R. Prasad. 1998. Identification of mutant alleles of *CaMDR1*, a major facilitator of *C. albicans* which confers multidrug resistance and its *in vitro* transcriptional activation. *Curr. Genet.* **34**:192–199.
- Gyurko, C., U. Lendenmann, E. J. Helmerhorst, R. F. Troxler, and F. G. Oppenheim. 2001. Killing of *Candida albicans* by Histatin 5: cellular uptake and energy requirement. *Antonie van Leeuwenhoek* **79**:297–309.
- Hauser, M., V. Narita, A. M. Donhardt, F. Naider, and J. Becker. 2001. Multiplicity and regulation of genes encoding peptide transporters in *Saccharomyces cerevisiae*. *Mol. Microbiol.* **18**:105–112.
- Henriques, S. T., M. N. Melo, and A. N. B. Canstano. 2006. Cell-penetrating peptides and antimicrobial peptides: how different are they? *Biochem. J.* **399**:1–7.
- Höfer, M., and P. C. Misra. 1978. Evidence for a proton/sugar symport in the yeast *Rhodotorula gracilis* (*glutinis*). *Biochem. J.* **172**:15–22.
- Horák, J. 1997. Yeast nutrient transporters. *Biochim. Biophys. Acta* **1331**:41–79.
- Imai, T., and T. Ohno. 1995. Measurements of yeast intracellular pH by image processing and the changes it undergoes during growth phase. *J. Biotechnol.* **38**:165–172.
- Kingsbury, W. D., J. C. Boehm, M. J. Mehta, and S. F. Grappel. 1983. Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine-peptide conjugates. *J. Med. Chem.* **26**:1725–1729.
- Krishnamurthy, S., U. Chatterjee, V. Gupta, R. Prasad, P. Das, P. Snehlata, S. E. Hasmain, and R. Prasad. 1998. Deletion of transmembrane domain 12 of *CDR1*, a multidrug transporter from *Candida albicans*, leads to altered

- drug specificity: expression of a yeast multidrug transporter in baculovirus expression system. *Yeast* **14**:535–550.
23. **Loeffler, J., and D. A. Stevens.** 2003. Antifungal drug resistance. *Clin. Infect. Dis.* **36**:31–41.
  24. **Li, X. S., J. N. Sun, K. Okamoto-Shibayama, and M. Edgerton.** 2006. *Candida albicans* cell wall Ssa proteins bind and facilitate import of human salivary histatin 5 required for toxicity. *J. Biol. Chem.* **281**:22453–22463.
  25. **Lichliter, W. D., F. Naider, and J. M. Becker.** 1976. Basis for the design of anticandidal agents from studies of peptide utilization in *Candida albicans*. *Antimicrob. Agents Chemother.* **10**:483–490.
  26. **McCarthy, P. J., D. J. Newman, L. J. Nisbet, and W. D. Kingsbury.** 1985. Relative rates of transport of peptidyl drugs by *Candida albicans*. *Antimicrob. Agents Chemother.* **28**:494–499.
  27. **Milewski, S., F. Mignini, R. Prasad, and E. Borowski.** 2001. Unusual susceptibility of a multidrug-resistant yeast strain to peptidic antifungals. *Antimicrob. Agents Chemother.* **45**:223–228.
  28. **Milewski, S., R. Andruszkiewicz, L. Kasprzak, J. Mazerski, F. Mignini, and E. Borowski.** 1991. Mechanism of action of anticandidal dipeptides containing inhibitors of glucosamine-6-phosphate synthase. *Antimicrob. Agents Chemother.* **35**:36–43.
  29. **Moneton, P., P. Sarthou, and F. Le Goffic.** 1986. Transport and hydrolysis of peptides in *Saccharomyces cerevisiae*. *J. Gen. Microbiol.* **132**:2147–2153.
  30. **National Committee for Clinical Laboratory Standards.** 2002. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed., vol. 22. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
  31. **Patterson, T. F.** 2005. Advances and challenges in management of invasive mycoses. *Lancet* **366**:1013–1025.
  32. **Payne, J. W., and T. M. Nisbet.** 1981. Continuous monitoring of substrate uptake by microorganisms using fluorescamine: application to peptide transport by *Saccharomyces cerevisiae* and *Streptococcus faecalis*. *J. Solid-Phase Biochem.* **3**:447–458.
  33. **Perlin, D. S., C. L. Brown, and J. E. Haber.** 1988. Membrane potential defect in hygromycin B-resistant *pma1* mutants of *Saccharomyces cerevisiae*. *J. Biol. Chem.* **263**:18118–18122.
  34. **Perry, J. R., M. A. Basrai, H.-Y. Steiner, F. Naider, and J. Becker.** 1994. Isolation and characterization of a *Saccharomyces cerevisiae* peptide transporter. *Mol. Cell. Biol.* **14**:104–115.
  35. **Pfaller, M. A., and D. J. Diekema.** 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin. Microbiol. Rev.* **20**:133–163.
  36. **Prasad, R., and K. Kapoor.** 2005. Multidrug resistance in yeast *Candida*. *Int. Rev. Cytol.* **242**:215–248.
  37. **Prasad, R., P. De Wergifosse, and A. Goffeau.** 1995. Molecular cloning and characterization of a novel gene of *Candida albicans*, CDR1 conferring multiple resistance to drugs and antifungals. *Curr. Genet.* **27**:320–329.
  38. **Regenberg, B., L. During-Olsen, M. C. Kielland-Brandt, and S. Holmberg.** 1999. Substrate specificity and gene expression of the amino-acid permeases in *Saccharomyces cerevisiae*. *Curr. Genet.* **36**:317–328.
  39. **Reuss, O., and J. Morschhäuser.** 2006. A family of oligopeptide transporters is required for growth of *Candida albicans* on proteins. *Mol. Microbiol.* **60**:795–812.
  40. **Sanglard, D., and J. Bille.** 2002. Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of *Candida* infections, p. 349–383. In R. A. Calderone (ed.), *Candida* and candidiasis, ASM Press, Washington, DC.
  41. **Serrano, R., M. C. Keilland-Brandt, and G. R. Fink.** 1986. Yeast plasma membrane ATPase is essential for growth and has homology with (Na<sup>+</sup> + K<sup>+</sup>), K<sup>+</sup>- and Ca<sup>2+</sup>- ATPases. *Nature (London)* **319**:689–693.
  42. **Smriti, S. Krishnamurthy, B. L. Dixit, C. M. Gupta, S. Milewski, and R. Prasad.** 2002. ABC transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen *Candida albicans* are general phospholipid translocators. *Yeast* **19**:303–318.
  43. **Ti, J. S., A. S. Steinfeld, F. Naider, A. Gulumoglu, S. V. Lewis, and J. M. Becker.** 1980. Anticandidal activity of pyrimidine-peptide conjugates. *J. Med. Chem.* **23**:913–918.
  44. **Viudes, A., J. Peman, E. Canton, P. Ubeda, J. L. Lopez-Ribot, and M. Gobernado.** 2002. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. *Eur. J. Clin. Microbiol. Infect. Dis.* **21**:767–774.
  45. **Wakieć, R., R. Prasad, J. Morschhäuser, F. Barchiesi, E. Borowski, and S. Milewski.** 2007. Voriconazole and multidrug resistance in *Candida albicans*. *Mycoses* **50**:109–115.
  46. **Yadan, J. C., M. Gonneau, P. Sarthou, and F. Le Goffic.** 1984. Sensitivity to nikkomycin Z in *Candida albicans*: role of peptide permeases. *J. Gen. Microbiol.* **160**:884–888.
  47. **Zheng, H., H. L. Zhang, J. M. Becker, F. Naider, and W. R. Farkas.** 1992. The lysine analog L-oxalysine is an inhibitor of RNA synthesis. *Int. J. Biochem.* **24**:145–149.